Bronchial asthma is a chronic inflammatory disease of the airways that causes recurring episodes of wheezing, chest tightness, coughing, and shortness of breath. The term “bronchial” simply specifies that the inflammation and narrowing occur in the bronchi, the branching tubes that carry air into the lungs, distinguishing it from the now-obsolete label “cardiac asthma.” Roughly 300 million people worldwide live with the condition, and the science behind it has shifted dramatically over the past few decades, from viewing asthma as a straightforward problem of twitchy airways to understanding it as a complex, multi-layered disease with distinct subtypes and triggers.
What Happens Inside the Airways
At its core, asthma involves two problems happening at once: inflammation and an exaggerated physical response by the muscles wrapped around the airways. Airway smooth muscle plays a central role. It is responsible for the acute bronchoconstriction that makes breathing difficult during an attack, and it becomes overly responsive to triggers, contracting harder and more readily than it should.1PubMed Central. Airway smooth muscle in the pathophysiology and treatment of asthma That tightening is paired with swelling of the airway lining, excess mucus production, and the arrival of immune cells that amplify the inflammation.
Over time, repeated cycles of inflammation and repair cause physical changes to the airway walls themselves. These structural changes, collectively called airway remodeling, include thickening of the basement membrane beneath the airway lining, overgrowth and enlargement of smooth muscle bundles, an increase in mucus-producing goblet cells, and the formation of new blood vessels within the airway wall.2PubMed Central. The Three A’s in Asthma – Airway Smooth Muscle, Airway Remodeling & Angiogenesis The airway lining itself can shed its protective cells, while fibroblasts underneath become activated and lay down scar-like tissue.3PubMed Central. Airway Remodeling in Asthma These changes are not just cosmetic damage; they narrow the airways permanently and make them stiffer, contributing to the progressive loss of lung function that some people with long-standing asthma experience.
While eosinophils and mast cells have long been recognized as key players in asthma’s inflammatory cascade, research has increasingly focused on a different immune cell: the neutrophil. Airway neutrophilia tends to track with disease severity and, critically, with asthma that does not respond well to corticosteroids, the drugs most people rely on for control.4Europe PMC. Neutrophilic Inflammation in Asthma and Association with Disease Severity This distinction between eosinophil-driven and neutrophil-driven inflammation matters enormously for treatment, as we will see.
What Causes Asthma and Who Gets It
There is no single cause. Asthma emerges from an interaction between inherited susceptibility and environmental exposure, and the balance between those two factors looks different from person to person. On the genetic side, researchers have identified several chromosomal regions linked to asthma risk. One of the best-replicated findings involves a stretch of DNA on chromosome 17 (the 17q12-q21 region), where variation in a gene called ZPBP2 influences how neighboring genes are expressed. Intriguingly, the way this region is chemically marked differs between males and females and changes with age, which may help explain why asthma’s sex distribution shifts over a person’s lifetime.5PubMed. Sex- and age-dependent DNA methylation at the 17q12-q21 locus associated with childhood asthma
That sex shift is striking: boys are more likely to develop asthma than girls, but after puberty the pattern reverses, and adult women carry a higher burden of both prevalence and severity.6PubMed Central. Sex Differences in Paediatric and Adult Asthma Hormonal fluctuations appear to play a role, though exactly how sex hormones modulate airway inflammation is still an active research question.
Environmental factors layer on top of genetics. Early-life exposure to indoor allergens, like dust mites, pet dander, and mold, is a strong predictor of developing asthma later in childhood, and the vast majority of children with asthma are sensitized to at least one indoor allergen.7PubMed Central. Indoor allergen exposure and asthma outcomes In the workplace, the picture is also significant: up to about 15% of all asthma cases have an occupational origin, with flour dust, animal proteins, and chemical compounds called isocyanates among the most common culprits.8PubMed. Exposure-response relationships of occupational inhalative allergens
One of the more fascinating developments in asthma research involves the gut microbiome. The so-called microflora hypothesis proposes that disruptions to the normal bacterial communities in infancy can push the immune system toward allergic responses. Animal studies have identified a critical early-life window during which gut microbial imbalance is most influential in promoting these hypersensitivity disorders.9PubMed Central. Asthma and the microbiome: defining the critical window in early life In humans, certain gut bacteria like Faecalibacterium and Bifidobacterium have been linked to asthma protection, and the short-chain fatty acids these microbes produce seem to support immune tolerance through a communication pathway between the gut and the lungs.10PubMed Central. Early-Life Host-Microbial Interactions and Asthma Development: A Lifelong Impact?
Not One Disease but Many
One of the biggest shifts in modern asthma science is the recognition that “asthma” is really an umbrella term covering several distinct disease patterns. Clinicians increasingly classify asthma by phenotype (observable characteristics like age of onset, triggers, and severity) and endotype (the underlying biological mechanism). The broadest split is between T2-high asthma, driven by a particular arm of the immune system that produces eosinophilic inflammation and elevated immunoglobulin E (IgE), and T2-low asthma, which may involve neutrophilic inflammation or relatively little inflammation at all.11PubMed Central. Biomarkers in Different Asthma Phenotypes This matters practically because the newest and most effective targeted therapies work well for T2-high disease but offer little for T2-low patterns, leaving a real treatment gap.
There is also a messy overlap zone. Some people develop features of both asthma and chronic obstructive pulmonary disease (COPD), a combination sometimes called asthma-COPD overlap. These patients tend to have more frequent flare-ups, worse outcomes, and higher healthcare use than people with either condition alone.12Wiley Online Library / Respirology. Asthma-COPD overlap syndrome (ACOS): A diagnostic challenge Diagnosing the overlap is tricky because no single test can separate it from its parent conditions, and diagnostic criteria vary from guideline to guideline.
How Asthma Is Diagnosed
Asthma diagnosis still rests on a combination of symptoms, physical examination, and lung function testing. Spirometry, which measures how quickly and forcefully you can blow air out of your lungs, remains the backbone. A key metric is how much air you can exhale in one second (FEV1) compared with your total forced exhalation. If that ratio is reduced and then improves significantly after inhaling a bronchodilator, the pattern is strongly suggestive of asthma.
Beyond spirometry, newer biomarkers are helping clinicians identify which type of asthma a person has and how active the inflammation is. Fractional exhaled nitric oxide (FeNO) is a breath test that reflects eosinophilic airway inflammation. Research has found a meaningful positive correlation between FeNO levels and blood eosinophil counts, and a negative correlation with FEV1, meaning higher FeNO tends to appear alongside worse airflow.13PubMed Central. The Correlation Between Fractional Exhaled Nitric Oxide (FeNO), Blood Eosinophil Count, Immunoglobulin E Levels, and Spirometric Values in Patients With Asthma When FeNO and blood eosinophil counts are used together, diagnostic accuracy improves further; moderately elevated levels of both (FeNO above 40 parts per billion and eosinophils above 300 cells per microliter) gave a specificity above 95% for diagnosing asthma in one study.14PubMed Central. Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma
How Treatment Has Changed
For decades, the standard approach to asthma was simple: use a quick-relief bronchodilator (a short-acting beta-agonist, or SABA) when symptoms flare, and take a daily inhaled corticosteroid if your asthma is persistent. That model has been substantially revised. The understanding that airway inflammation drives the disease, not just airway muscle spasm, reshaped treatment priorities. Once clinicians recognized inflammation as the underlying problem, controller therapies like inhaled corticosteroids became the centerpiece of management.15PubMed Central. A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis
The most significant recent change in everyday asthma care is the rise of what’s called SMART therapy: using a single combination inhaler containing both an inhaled corticosteroid and a long-acting bronchodilator (specifically budesonide-formoterol) as both your daily controller and your rescue inhaler. A meta-analysis of over 22,000 patients found that SMART reduced the risk of asthma exacerbations by about a third compared with using the same dose of controller medication plus a separate SABA rescue inhaler.16JAMA. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma In patients whose asthma was poorly controlled, switching to SMART was associated with roughly a 30% lower risk of severe exacerbation compared with stepping up conventional treatment.17JAMA Network Open. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma A network meta-analysis covering mild through severe asthma ranked SMART as the top option for reducing exacerbation risk across severity levels.18European Respiratory Journal. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis
The flipside of this evolution is a growing concern about over-reliance on SABA rescue inhalers. A systematic review and meta-analysis found that people using three or more SABA canisters per year had roughly double the risk of death and double the rate of acute exacerbations compared with those using fewer.19PubMed Central. Adverse Outcomes Associated With Short‐Acting Beta‐Agonist Overuse in Asthma High SABA use is now widely viewed as a red flag indicating that a person’s underlying inflammation is not being adequately controlled, not just a sign that they need more relief.
Biologic Therapies and Procedures for Severe Asthma
For the roughly 5-10% of asthma patients whose disease remains uncontrolled despite maximized conventional therapy, biologic medications have been transformative. These are injectable drugs that target specific molecules in the inflammatory cascade. Three of the most established are omalizumab (which blocks IgE), mepolizumab (which targets a chemical signal called interleukin-5 that drives eosinophil production), and dupilumab (which blocks interleukin-4 and interleukin-13, two key drivers of T2 inflammation). A systematic review found that among these three, dupilumab was associated with the lowest rates of asthma exacerbations across various phenotypes, and both dupilumab and mepolizumab had more favorable safety profiles than omalizumab, which carries an FDA warning for the risk of anaphylaxis.20PubMed Central. Safety and Efficacy of Dupilumab, Omalizumab, and Mepolizumab in Moderate-to-Severe Asthma: A Systematic Review
A more invasive option for severe asthma is bronchial thermoplasty, a procedure that delivers controlled heat to the airway walls through a bronchoscope, aiming to reduce the bulk of smooth muscle. A Cochrane review found a modest improvement in quality-of-life scores and a reduction in severe exacerbations in the year following treatment. However, the procedure itself comes with a catch: during the treatment period and the six weeks afterward, patients experienced increased asthma symptoms and a roughly 3.5-fold greater risk of hospitalization for asthma. After that initial window, the hospitalization risk leveled off.21PubMed Central. Recent Developments In Bronchial Thermoplasty For Severe Asthma Thermoplasty remains a niche option, generally reserved for people who have exhausted other treatments.
Non-Drug Approaches That Hold Up
Medication is the foundation of asthma management, but several non-drug strategies have earned genuine evidence support. An umbrella review spanning research across the lifespan identified a few standouts with high-level evidence: prenatal vitamin D supplementation reduced the risk of offspring developing asthma, digital health tools (such as app-based self-management programs) improved asthma control from childhood through older adulthood, and breathing exercises improved quality of life, symptoms, and lung function in adults.22PubMed Central. Non-pharmacological interventions for asthma prevention and management across the life course: Umbrella review
A network meta-analysis comparing different non-drug interventions head-to-head found that breathing training was the most likely to improve asthma control test scores, mind-body therapies (like yoga and tai chi) ranked highest for improving certain lung function measures, and biopsychosocial approaches (which combine psychological support with physical management) showed benefits for overall lung capacity and peak airflow.23PubMed Central. Impact of non-pharmacological adjuvant interventions on adult asthma patients: a systematic review and network meta-analysis Nutritional interventions centered on fruit and vegetable intake and antioxidant supplementation have also been proposed, alongside psychological support for the emotional burden that chronic asthma can carry.24PubMed Central. Basis of preventive and non-pharmacological interventions in asthma None of these replace inhalers, but they can meaningfully improve control and quality of life when layered on top of standard treatment.
Why Viruses Are the Biggest Trigger for Flare-Ups
If you have asthma, the thing most likely to send you to the emergency room is not dust or pollen. It is a respiratory virus. Viruses have been identified as the cause behind the vast majority of asthma exacerbations.25PubMed Central. Asthma exacerbation related to viral infections: An up to date summary Rhinoviruses, the common cold viruses, are the most frequent culprits, especially in children. A viral infection amplifies the underlying airway inflammation, triggers mucus overproduction, and can temporarily worsen the hyperresponsiveness that is already present in asthmatic airways. This is one reason why maintaining good baseline control with anti-inflammatory medication matters so much: when a virus inevitably hits, a well-controlled airway is far more resilient than a chronically inflamed one.
Climate Change and Asthma
The environmental context of asthma is shifting. Climate change is intensifying drought, wildfires, dust storms, and thunderstorms, all of which increase air pollution, extend pollen seasons, raise pollen and mold concentrations, and may even make pollen itself more allergenic.26PubMed. The Role of Climate Change in Asthma A systematic review and meta-analysis quantified the relationship: extreme weather events were associated with roughly an 18% increase in asthma-related events overall, a 25% increase in asthma emergency department visits, and a striking 2.1-fold increase in asthma mortality. Children and women appeared particularly vulnerable, and thunderstorms alone raised the risk of asthma events by about 24%.27European Respiratory Review. Extreme weather and asthma: a systematic review and meta-analysis Thunderstorm asthma is a real phenomenon: sudden storms can rupture pollen grains into tiny fragments that penetrate deep into the lungs, triggering mass casualty events in sensitized populations. Melbourne, Australia experienced one of the most dramatic episodes in 2016, with thousands of emergency presentations in a single evening.
The Global Access Gap
The majority of people with asthma live in low- and middle-income countries, and those countries bear a disproportionate share of asthma-related suffering and death. The reason is starkly simple: essential inhaled medications, particularly those containing corticosteroids, are often unavailable or unaffordable.28PubMed Central. Asthma management in low and middle income countries: case for change A systematic review of medicine availability across low- and middle-income countries found that only a handful met even a basic 80% availability target for short-acting rescue inhalers, and even fewer met it for inhaled corticosteroids. Combination inhalers, the kind used in SMART therapy, met the target in zero of the countries surveyed. In terms of cost, a SABA inhaler could represent one to four days’ wages, inhaled corticosteroids two to seven days’ wages, and combination inhalers at least six days’ wages.29The Lancet Global Health. Availability, cost, and availability of essential medicines for asthma and chronic obstructive pulmonary disease in low-income and middle-income countries: a systematic review
This creates a grim irony: the very medications shown to reduce exacerbations and save lives are least available where the burden is highest. In many low-resource settings, there is no healthcare infrastructure to deliver chronic disease management at all, and the market dynamics that might bring drug prices down have not materialized.30The Lancet Respiratory Medicine. Non-communicable respiratory diseases For children, who make up a large proportion of the population in many of these regions, uncontrolled asthma means missed school, limited activity, and a trajectory of lung damage that compounds over a lifetime. The scientific understanding of asthma has never been better, but translating that understanding into equitable care remains one of the disease’s biggest unresolved challenges.